Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IMpower131

Roche Basel Switzerland

Roche undercuts price of Bayer cancer drug after winning FDA approval

Both drugs highly effective in small subset of patients

- PMLiVE

Tagrisso tops rival drugs on survival in first-line lung cancer

Takes fight to Pfizer's Vizimpro

- PMLiVE

Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund

Proves continuing dominance in this indication

- PMLiVE

Positive first-line phase 3 results for Tecentriq

Hopes to extend use in bladder cancer

- PMLiVE

Roche reveals yet another Spark takeover delay

Are concerns about haemophilia dominance the cause?

- PMLiVE

Keytruda scores in neoadjuvant triple negative breast cancer combo

Tecentriq still in pole position

Roche Basel Switzerland

New products help lift Roche outlook despite biosimilar onslaught

Two new cancer therapies approved in Q2

- PMLiVE

Genentech taps into Sosei Heptares GPCR expertise with $1bn alliance

Targeting largest family of proteins in cell membranes

Roche - Basel

Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy

First-in-class antibody drug conjugate

Roche Basel Switzerland

Roche/GE’s digital medicine alliance bears first fruit

While new player enters liquid biopsy market

- PMLiVE

Genentech forges $800m autoimmune alliance with Parvus

Big vote of confidence in novel platform

- PMLiVE

Roche and NHS England hail pricing deal on MS drug Ocrevus

Another pricing deal on high cost medicine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links